The data on the use of tipranavir and enfuvirtide in pregnancy are very limited. We performed a pharmacokinetic profile in a pregnant woman with multidrug-resistant HIV-1 infection at 37 weeks gestation. Tipranavir levels were in the therapeutic range and the cord blood concentration at delivery was relatively high when compared with other protease inhibitors. No enfuvirtide was detected in the fetal compartment. Tipranavir and enfuvirtide were successfully used in pregnancy, but possible toxicities must be kept in mind.
WarszawskiJ, TubianaR, Le ChenadecJ.Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort.AIDS2008; 22: 289–99
2.
WensingAMJ, BoucherCAB, van KasterenM, van DijkenPJ, GeelenSP, JuttmannJR.Prevention of mother-to-child transmission of multi-drug resistant HIV-1 using maternal therapy with both enfuvirtide and tipranavir.AIDS2006; 20: 1465–7
3.
Boehringer Ingelheim International GmbH.Aptivus® (tipranavir) Capsules - Summary of Product Characteristics (SPC), 2007
4.
GingelmaierA, KurowskiM, KästnerR.Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.AIDS2006; 20: 1737–43
5.
RipamontiD, CattaneoD, MaggioloF.Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.AIDS2007; 21: 2409–15
6.
MeyohasMC, LacombeK, CarbonneB, Morand-JoubertL, GirardPM.Enfuvirtide prescription at the end of pregnancy to a multi-treated HIV-infected woman with virological breakthrough.AIDS2004; 18: 1966–8
7.
Brennan-BensonP, PakianathanM, RiceP.Enfuvirtide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta.AIDS2006; 20: 297–9
8.
CeccaldiPF, FerreiraC, GavardL, GilS, PeytavinG, MandelbrotL.Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model.Am J Obstet Gynecol2008; 198: 433.e1-e2
